c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Products of "c-Met/HGFR"
Sort by
Afatinib Dimaleate
CAS:Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Formula:C32H33ClFN5O11Purity:100% - 98.11%Color and Shape:SolidMolecular weight:718.08Ref: TM-T1773
1g467.00€5mg40.00€10mg59.00€25mg87.00€50mg107.00€100mg140.00€200mg188.00€500mg313.00€1mL*10mM (DMSO)66.00€Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formula:C29H49N4O10PPurity:97.05%Color and Shape:SolidMolecular weight:644.69Ref: TM-T39507L
1mg116.00€2mg160.00€5mg238.00€10mg353.00€25mg563.00€50mg758.00€100mg1,017.00€200mg1,359.00€Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formula:C20H15F3N8Purity:99.16%Color and Shape:SolidMolecular weight:424.38Ref: TM-T10585
1mg97.00€5mg216.00€10mg354.00€25mg628.00€50mg905.00€100mg1,264.00€200mg1,700.00€1mL*10mM (DMSO)240.00€c-Met-IN-2
CAS:c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Formula:C24H21FN10OPurity:98%Color and Shape:SolidMolecular weight:484.49PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formula:C51H54N10O7Color and Shape:SolidMolecular weight:919.037(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFormula:C15H14N2OPurity:96.09% - ≥95%Color and Shape:SolidMolecular weight:238.28Ref: TM-T2496
1mg57.00€5mg111.00€10mg188.00€25mg331.00€50mg568.00€100mg695.00€200mg948.00€1mL*10mM (DMSO)144.00€MK-2461
CAS:MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with anFormula:C24H25N5O5SPurity:95.41% - 99.53%Color and Shape:SolidMolecular weight:495.55Ref: TM-T6094
1mg52.00€5mg120.00€10mg187.00€25mg363.00€50mg552.00€100mg842.00€200mg1,130.00€1mL*10mM (DMSO)134.00€NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formula:C20H16N6Purity:100% - 98.61%Color and Shape:SolidMolecular weight:340.38Ref: TM-T2680
2mg44.00€5mg74.00€10mg97.00€25mg178.00€50mg255.00€100mg359.00€200mg510.00€1mL*10mM (DMSO)84.00€AMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Formula:C23H22FN7O3Purity:99.26% - 99.9%Color and Shape:SolidMolecular weight:463.46Ref: TM-T3209
1mg40.00€2mg52.00€5mg85.00€10mg124.00€25mg197.00€50mg350.00€100mg522.00€200mg748.00€1mL*10mM (DMSO)86.00€MET/PDGFRA-IN-2
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positiveFormula:C29H29N7OPurity:98%Color and Shape:SolidMolecular weight:491.59c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37
